Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

Unmet Needs in Managing MDD Interpreting Thyroid Function Tests Using Thyroid Lab Tests Testing & Screening to Optimize Men's Health

AHA 2019: 11 Late Breaking Clinical Trials At-a-Glance

November 21, 2019

Grace Halsey

Slideshow

AHA 2019 ICYMI: Summaries of 11 late-breaking clinical trials presented at the 2019 Scientific Sessions held in Philadelphia, PA, Nov 16-18.

Investigational Nasal Spray Found Safe, Effective for Self-Treatment of Paroxysmal Supraventricular Tachycardia

September 27th 2023

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

August 30th 2023

Biosimilar Liraglutide Noninferior to Reference Product in Persons with Type 2 Diabetes: Phase 3 Trial

September 25th 2023

Investigational Nasal Spray Found Safe, Effective for Self-Treatment of Paroxysmal Supraventricular Tachycardia

September 27th 2023

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

August 30th 2023

Biosimilar Liraglutide Noninferior to Reference Product in Persons with Type 2 Diabetes: Phase 3 Trial

September 25th 2023

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

October 29th 2020

Daily Dose: High Blood Pressure While Lying Down Raises Risk for CVD Events

September 18th 2023

Daily Dose: Worldwide Burden of Atrial Fibrillation Doubled Over 30 Years

September 12th 2023

Investigational Nasal Spray Found Safe, Effective for Self-Treatment of Paroxysmal Supraventricular Tachycardia

September 27th 2023

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

August 30th 2023

Biosimilar Liraglutide Noninferior to Reference Product in Persons with Type 2 Diabetes: Phase 3 Trial

September 25th 2023

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

October 29th 2020

Daily Dose: High Blood Pressure While Lying Down Raises Risk for CVD Events

September 18th 2023

Daily Dose: Worldwide Burden of Atrial Fibrillation Doubled Over 30 Years

September 12th 2023

Related Content

Investigational Nasal Spray Found Safe, Effective for Self-Treatment of Paroxysmal Supraventricular Tachycardia

September 27th 2023

Article

Etripamil 70 mg nasal spray restored heart rate within 30 minutes in approximately 60% of PSVT episodes, report authors of new study.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

August 30th 2023

Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Biosimilar Liraglutide Noninferior to Reference Product in Persons with Type 2 Diabetes: Phase 3 Trial image credit ©PARATA/stock.adobe.com

September 25th 2023

Article

The biosimilar to the GLP-1 mimetic Victoza proved noninferior for reduction of HbA1c and had similar positive effects on body weight, lipids, and blood pressure.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

October 29th 2020

Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.